Nevirapin Aurobindo (Nevirapine)

Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme. This binding changes the enzyme’s shape, preventing it from converting viral RNA into DNA, a step essential for HIV replication. By blocking this process, nevirapine helps lower the amount of virus in the body.

The exact dose is determined by the prescribing clinician based on current treatment guidelines, patient weight, age, and clinical status. Typically, adults start with a lower dose for the first two weeks to reduce rash risk, then increase to the maintenance dose, but the prescriber sets the final regimen.

Nevirapine can be used during pregnancy, especially in the first trimester, but it requires careful monitoring of liver function and rash risk. Breastfeeding while on nevirapine is generally considered acceptable, yet clinicians should evaluate the benefits and potential risks for each mother‑infant pair.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Compared with efavirenz, another NNRTI, nevirapine has a lower risk of central nervous system side effects but a higher incidence of skin rash and liver enzyme elevations. Choice between them depends on patient tolerance, comorbidities, and potential drug‑drug interactions, and should be guided by the treating physician.

Store the tablets at ambient temperature below 25 °C, in the original container, and protect them from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity to maintain potency.

Nevirapin Aurobindo is taken orally, usually with food to reduce gastrointestinal upset. The tablets are swallowed whole with a full glass of water. Dosing schedules, including any loading phase, are defined by the prescribing clinician based on individual treatment plans.

The most serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening liver injury. Patients should be instructed to seek immediate medical attention if they develop widespread rash, fever, jaundice, or unexplained fatigue.

Nevirapine is contraindicated in individuals with a known hypersensitivity to the drug or any NNRTI, and in patients with pre‑existing severe liver disease. It should also be avoided in pregnant women beyond the first trimester unless the benefits outweigh the risks, and in patients with a CD4 count above recommended thresholds who are at higher risk for rash.